)
Immunovant (IMVT) investor relations material
Immunovant Q2 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Development focus shifted fully to IMVT-1402 after batoclimab was discontinued in April 2026; no product revenue has been generated.
IMVT-1402 600 mg met the Week 28 primary endpoint in difficult-to-treat RA; $722.3M in cash was expected to fund the current plan through a potential Graves’ disease launch.
Financial highlights
Q2 operating expenses were $104.2M vs. $131.8M YoY; net loss was $97.2M vs. $126.5M, and loss per share was $0.47 vs. $0.73.
Q2 R&D was $85.0M vs. $114.2M YoY, reflecting batoclimab wind-down and manufacturing-cost timing; G&A rose to $19.1M from $17.5M, partly due to pre-commercial investment.
H1 operating expenses were $264.5M vs. $259.0M; net loss was $250.5M vs. $247.1M, and loss per share was $1.22 vs. $1.43.
H1 R&D was $227.6M vs. $215.4M, primarily reflecting IMVT-1402 trials and manufacturing; G&A was $36.8M vs. $43.5M.
Cash and cash equivalents were $722.3M at September 30, 2026, down from $902.1M at March 31; H1 operating cash use was $207.6M.
Outlook and guidance
Current cash was expected to fund the operating plan through potential IMVT-1402 launch in Graves’ disease; potential expansion after D2T RA results was not included, with updated runway guidance expected if plans are finalized.
Top-line results are expected in 2027 for Graves’ disease and myasthenia gravis, and in 2028 for CIDP.
FDA discussions on the D2T RA registrational path were planned for later in 2026; trial design and development plans remain subject to regulatory alignment.
Advancement in Sjögren’s beyond the ongoing, fully enrolled Phase 2 trial is considered unlikely.
- IMVT-1402 advances across four indications, with positive D2T RA results and ~$722M cash.IMVT
Corporate presentation - IMVT-1402 targets major autoimmune diseases with best-in-class efficacy and broad market potential.IMVT
Corporate presentation - IMVT-1402 is poised to lead in autoimmune therapy with deep IgG reduction and broad clinical potential.IMVT
Roivant Investor Day presentation - Imminent brepocitinib DM launch and advancing IMVT-1402 trials drive a pivotal, cash-rich period.IMVT
Q1 2027 - IMVT-1402 targets major autoimmune diseases with best-in-class efficacy and broad clinical reach.IMVT
Corporate presentation - Virtual annual meeting to vote on directors, auditor, and executive pay, all board-recommended.IMVT
Proxy filing - Proxy covers director elections, auditor ratification, and executive pay, emphasizing governance.IMVT
Proxy filing - Five INDs cleared for IMVT-1402, with $472.9M cash and pivotal trials imminent.IMVT
Q2 2025 - IMVT-1402 achieved high response rates in uncontrolled Graves', with pivotal trial set for year-end.IMVT
Status Update
)
)
)
)
)
)
)
)